World Investment Advisors LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

World Investment Advisors LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3,765.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 288,608 shares of the medical research company’s stock after acquiring an additional 281,141 shares during the period. World Investment Advisors LLC’s holdings in Amgen were worth $92,992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in shares of Amgen during the 3rd quarter valued at approximately $25,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen during the second quarter worth $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen in the second quarter worth $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen during the second quarter worth $33,000. Finally, Matrix Trust Co acquired a new position in Amgen during the third quarter worth $36,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AMGN. Royal Bank of Canada decreased their price objective on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Truist Financial lowered Amgen from a “buy” rating to a “hold” rating and boosted their price target for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. TD Cowen increased their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $323.05.

Amgen Trading Down 0.6 %

Shares of AMGN stock opened at $272.58 on Friday. The company has a market cap of $146.52 billion, a PE ratio of 34.90, a P/E/G ratio of 3.08 and a beta of 0.55. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a fifty-two week low of $257.80 and a fifty-two week high of $346.85. The stock’s fifty day moving average price is $307.58 and its two-hundred day moving average price is $316.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $4.96 EPS. Equities analysts predict that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.30%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.